{"id":52161,"date":"2020-07-18T18:51:03","date_gmt":"2020-07-18T16:51:03","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=52161"},"modified":"2020-07-19T10:21:56","modified_gmt":"2020-07-19T08:21:56","slug":"aifa-tetto-spesa-farmaceutica-convenzionata-fabbisogno-sanitario-nazionale","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/aifa-tetto-spesa-farmaceutica-convenzionata-fabbisogno-sanitario-nazionale\/","title":{"rendered":"AIFA. Pharmaceutical spending ceiling (7.96% of the national health requirement)"},"content":{"rendered":"<p>AIFA carries out monthly monitoring of pharmaceutical expenditure data and communicates the related results to the Ministry of Health and the Ministry of Economy and Finance with the same frequency.<\/p>\n<p>The document is divided into 7 sections:<\/p>\n<p><a href=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg02.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-52164 alignright\" src=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg02-1024x861.jpg\" alt=\"\" width=\"480\" height=\"403\" srcset=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg02-1024x861.jpg 1024w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg02-300x252.jpg 300w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg02-768x646.jpg 768w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg02-1536x1292.jpg 1536w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg02-2048x1723.jpg 2048w\" sizes=\"auto, (max-width: 480px) 100vw, 480px\" \/><\/a>1. Verification of the Pharmaceutical Expenditure ceiling (7.96% of the national health requirement) calculated on the final 2019 FSN (amount equal to 113,791,926,183. The data is updated to 24 March 2020 as communicated by the MdS).<br \/>\n2. Verification of the Pharmaceutical Expenditure Ceiling for direct purchases net of medicinal gases (6.69% of the national health requirement) calculated on the final 2019 FSN.<br \/>\n3. Expenditure on Innovative drugs and verification of any excess expenditure with respect to the innovative non-oncological funds and the innovative oncological drug fund envisaged by Law 232 of 11 December 2016.<br \/>\n4. Verification of the Pharmaceutical Expenditure Ceiling for direct purchases of medicinal gases (0.20% of the national health requirement) calculated on the final 2019 FSN.<br \/>\n5. Overall pharmaceutical expenditure January-December 2019 and verification of compliance with overall resources.<br \/>\n6. Source of data.<br \/>\n7. Appendix.<\/p>\n<p><a href=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg03.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-52166 alignleft\" src=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg03-1024x861.jpg\" alt=\"\" width=\"543\" height=\"457\" srcset=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg03-1024x861.jpg 1024w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg03-300x252.jpg 300w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg03-768x645.jpg 768w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg03-1536x1291.jpg 1536w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg03-2048x1721.jpg 2048w\" sizes=\"auto, (max-width: 543px) 100vw, 543px\" \/><\/a>The net approved pharmaceutical expenditure borne by the NHS in the period January-December 2019 calculated net of discounts, total sharing (regional tickets and sharing of the reference price) and the 1.83% payback paid to the Regions by pharmaceutical companies, amounted to 7,765.3 million euros (table 1 and column M of table 7), showing a decrease compared to the previous year (-16.2 million euros). Consumption, expressed in number of recipes (570.3 million recipes), shows a reduction (-1.0%) compared to 2018; the incidence of the total ticket also decreased (-1.6%).<\/p>\n<p><span style=\"color: #000000;\">Table 3<\/span> Summary of net subsidized pharmaceutical expenditure in the period January-December 2019, in the individual regions, compared to the same period of 2018<\/p>\n<p>There<span style=\"color: #000000;\"> table 4a<\/span> indicates, for each Region, a set of indicators of expenditure and per capita consumption of the approved pharmaceutical, considering the weighted population for the year 2019.<\/p>\n<p><a href=\"https:\/\/www.aifa.gov.it\/governo-spesa-farmaceutica\" target=\"_blank\" rel=\"noopener noreferrer\">For other useful information, see the AIFA text<\/a><\/p>\n<p>by clicking here: <a href=\"https:\/\/www.aifa.gov.it\/documents\/20142\/847405\/CDA_Monitoraggio_Gennaio-Dicembre+2019_Consuntivo.pdf\/aca9f7c8-9bcc-1eba-ea7a-8712878df6ff\" target=\"_blank\" rel=\"noopener noreferrer\">complete document<\/a><\/p>\n<p><a href=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg04.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-52165 aligncenter\" src=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg04-1024x927.jpg\" alt=\"\" width=\"710\" height=\"642\" srcset=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg04-1024x927.jpg 1024w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg04-300x272.jpg 300w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg04-768x695.jpg 768w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg04-1536x1391.jpg 1536w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2020\/07\/aifa-pg04-2048x1855.jpg 2048w\" sizes=\"auto, (max-width: 710px) 100vw, 710px\" \/><\/a><\/p>\n<p>Note: <em>to enlarge the tables click on them<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>L&#8217;AIFA effettua il monitoraggio mensile dei dati di spesa farmaceutica e comunica le relative risultanze al Ministero della salute ed al Ministero dell&#8217;economia e delle finanze con la medesima cadenza. Il documento \u00e8 articolato in 7 sezioni: 1. Verifica del Tetto della Spesa farmaceutica convenzionata (7,96% del fabbisogno sanitario nazionale) calcolata su FSN 2019 definitivo &hellip;<\/p>","protected":false},"author":495,"featured_media":52163,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[49,26],"class_list":["post-52161","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-aifa","tag-spesa-farmaceutica"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/52161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/495"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=52161"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/52161\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/52163"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=52161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=52161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=52161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}